Demo Data from EDBT 2026 / reviewers in the wild / expert
Ronald G. Tompkins
dblp:151/5761
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2014
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 4 heaviest of 4, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › proteomics › proteome comparison
differential protein expression analysis |
0.2 | 1 | 2014 | Detecting differential protein expression in large-scale population proteomics · Bioinform. 2014 |
Bioinformatics and computational biology › biostatistics
missing data handling |
0.2 | 1 | 2014 | Detecting differential protein expression in large-scale population proteomics · Bioinform. 2014 |
Bioinformatics and computational biology
proteomics |
0.2 | 1 | 2014 | Detecting differential protein expression in large-scale population proteomics · Bioinform. 2014 |
Bioinformatics and computational biology › biomarker discovery
clinical biomarker discovery |
0.1 | 1 | 2014 | Detecting differential protein expression in large-scale population proteomics · Bioinform. 2014 |
Methods — techniques the papers use, named apart from their topics
statistical modeling · 0.2significance analysis · 0.2
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2014 | Detecting differential protein expression in large-scale population proteomicsabstractMOTIVATION: Mass spectrometry (MS)-based high-throughput quantitative proteomics shows great potential in large-scale clinical biomarker studies, identifying and quantifying thousands of proteins in biological samples. However, there are unique challenges in analyzing the quantitative proteomics data. One issue is that the quantification of a given peptide is often missing in a subset of the experiments, especially for less abundant peptides. Another issue is that different MS experiments of the same study have significantly varying numbers of peptides quantified, which can result in more missing peptide abundances in an experiment that has a smaller total number of quantified peptides. To detect as many biomarker proteins as possible, it is necessary to develop bioinformatics methods that appropriately handle these challenges. RESULTS: We propose a Significance Analysis for Large-scale Proteomics Studies (SALPS) that handles missing peptide intensity values caused by the two mechanisms mentioned above. Our model has a robust performance in both simulated data and proteomics data from a large clinical study. Because varying patients' sample qualities and deviating instrument performances are not avoidable for clinical studies performed over the course of several years, we believe that our approach will be useful to analyze large-scale clinical proteomics data. AVAILABILITY AND IMPLEMENTATION: R codes for SALPS are available at http://www.stanford.edu/%7eclairesr/software.html. So Young Ryu, Wei-Jun Qian, David G. Camp II, Richard D. Smith, Ronald G. Tompkins, Ronald W. Davis, Wenzhong Xiao |
Bioinform. | 5 |